Skip to main content

Molecular Biotechnology: From DNA Sequence to Therapeutic Protein

  • 111k Accesses

Abstract

Therapeutic proteins have become a very valuable addition to the repertoire of drugs to treat patients with severe diseases. Therapeutic proteins differ in many aspects from classical, small molecule drugs. They differ, for example, in molecular size, uniformity of the active, production, purification, contaminations, side effects, stability, formulation, regulatory aspects, and price.

This chapter describes basic elements of the selection, design, cloning and production of biopharmaceuticals. The importance of the expression host in relation to specific post-translational modifications, such as the formation of disulfide bridges and glycosylation, is discussed. And finally, we describe the molecular biological aspects of the design and production of (humanized) monoclonal antibodies in cell culture.

Keywords

  • Therapeutic protein
  • Expression host
  • Post-translational modification
  • PCR
  • Humanized monoclonal antibody

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-00710-2_1
  • Chapter length: 18 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   89.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-00710-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   119.99
Price excludes VAT (USA)
Figure 1.1
Figure 1.2
Figure 1.3
Figure 1.4
Figure 1.5
Figure 1.6
Figure 1.7
Figure 1.8
Figure 1.9
Figure 1.10
Figure 1.11
Figure 1.12
Figure 1.13
Figure 1.14
Figure 1.15

Suggested Reading

  • Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52–62

    CAS  CrossRef  Google Scholar 

  • EvaluatePharma® World Preview 2017 (2017) Outlook to 2022. http://info.evaluategroup.com/rs/607-YGS-364/images/WP17.pdf. Accessed 3 Apr 2018.

  • GAciarz A, Khatri NK, Velez-Superbie ML, Saaranen MJ, Uchida Y, Keshavarz-Moore E, Ruddock LW (2017) Efficient soluble expression of disulfide bonded proteins in the cytoplasm of Escherichia coli in fed batch fermentations on chemically defined minimal media. Microbio Cell Fact 16:108

    CrossRef  Google Scholar 

  • Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting-a new approach to antibody humanization. Methods 36(1):2–34

    CrossRef  Google Scholar 

  • Kim JY, kim Y-G, Lee GM (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93:917–930

    CAS  CrossRef  Google Scholar 

  • Kircher M, Kelso J (2010) High-throughput DNA sequencing-concepts and limitations. Bioessays 32(6):524–536

    CAS  CrossRef  Google Scholar 

  • Kunert R, Reinhart D (2016) Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol 100:3451–3461

    CAS  CrossRef  Google Scholar 

  • Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7(1):21–39

    CAS  CrossRef  Google Scholar 

  • Lodish H, Berk A, Kaiser CA, Krieger M, Scott MP (2007) Molecular cell biology, 6th edn. WH. Freeman & CO, New York

    Google Scholar 

  • Nothaft H, Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8(11):765–778

    CAS  CrossRef  Google Scholar 

  • Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214

    CAS  CrossRef  Google Scholar 

  • Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 5(172):1–17

    Google Scholar 

  • Strohl WR, Knight DM (2009) Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 20(6):668–672

    CAS  CrossRef  Google Scholar 

  • Wells EA, Robinson AS (2017) Cellular engineering fro therapeutic protein production: product quality, host modification, and process improvement. Biotechnol J 12:16001015, 1–16001015,12

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronald S. Oosting .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Oosting, R.S. (2019). Molecular Biotechnology: From DNA Sequence to Therapeutic Protein. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, Cham. https://doi.org/10.1007/978-3-030-00710-2_1

Download citation